LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Search

Pfizer

Uždarymo kaina

SektoriusSveikatos priežiūra

26.98 -1.57

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

26.8

Max

27

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-5.2B

-1.6B

Pardavimai

903M

18B

P/E

Sektoriaus vid.

19.566

57.833

Pelnas, tenkantis vienai akcijai

0.66

Dividendų pajamingumas

6.47

Pelno marža

-9.387

Darbuotojai

75,000

EBITDA

-4.9B

756M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+4.96% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

6.47%

2.47%

Kitas uždarbis

2026-04-28

Kitas dividendų mokėjimo data

2026-06-12

Kita Ex Dividend data

2026-05-08

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-269M

151B

Ankstesnė atidarymo kaina

28.55

Ankstesnė uždarymo kaina

26.98

Naujienos nuotaikos

By Acuity

52%

48%

275 / 350 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Pfizer Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-03 12:25; UTC

Uždarbis

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

2026-01-20 10:40; UTC

Įsigijimai, susijungimai, perėmimai

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update

2026-01-20 07:47; UTC

Įsigijimai, susijungimai, perėmimai

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

2026-03-11 11:02; UTC

Rinkos pokalbiai

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

2026-03-10 12:50; UTC

Uždarbis

BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm. -- Barrons.com

2026-03-10 11:18; UTC

Uždarbis

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. -- Barrons.com

2026-03-09 09:43; UTC

Karštos akcijos

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

2026-02-10 21:51; UTC

Uždarbis

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

2026-02-10 21:17; UTC

Uždarbis

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

2026-02-03 21:36; UTC

Uždarbis

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

2026-02-03 19:56; UTC

Uždarbis

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026-02-03 19:46; UTC

Uždarbis

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

2026-02-03 17:35; UTC

Uždarbis

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026-02-03 17:30; UTC

Uždarbis

These Stocks Are Today's Movers: Palantir, PayPal, Novo Nordisk, Pfizer, Merck, AMD, Gartner, and More -- Barrons.com

2026-02-03 13:50; UTC

Uždarbis

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026-02-03 13:06; UTC

Uždarbis

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026-02-03 12:45; UTC

Uždarbis

These Stocks Are Today's Movers: Palantir, PayPal, Teradyne, Tesla, Pfizer, AMD, Merck, and More -- Barrons.com

2026-02-03 12:02; UTC

Uždarbis

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026-02-03 11:48; UTC

Uždarbis

Pfizer: About 20 Key Pivotal Study Starts Planned for 2026 >PFE

2026-02-03 11:48; UTC

Uždarbis

Pfizer: Enters 2026 With Clear Strategic Priorities, Growing Late-Stage Pipeline >PFE

2026-02-03 11:47; UTC

Uždarbis

Pfizer: Current Financial Guidance Doesn't Anticipate Any Stock Buybacks in 2026 >PFE

2026-02-03 11:46; UTC

Uždarbis

Pfizer Sees 2026 Adjusted R&D Expenses $10.5B-$11.5B >PFE

2026-02-03 11:45; UTC

Uždarbis

Pfizer Reaffirms 2026 Guidance >PFE

2026-02-03 11:45; UTC

Uždarbis

Pfizer 4Q Rev $17.56B >PFE

2026-02-03 11:45; UTC

Uždarbis

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

2026-02-03 11:45; UTC

Uždarbis

Pfizer 4Q Adj EPS 66c >PFE

2026-02-03 11:45; UTC

Uždarbis

Pfizer 4Q Loss/Shr 29c >PFE

2026-02-03 11:45; UTC

Uždarbis

Pfizer 4Q Loss $1.65B >PFE

2026-02-03 11:45; UTC

Uždarbis

Pfizer Sees FY Rev $59.5B-$62.5B >PFE

2026-02-03 10:41; UTC

Uždarbis

These Stocks Are Today's Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, DaVita, and More -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Pfizer Prognozė

Kainos tikslas

By TipRanks

4.96% į viršų

12 mėnesių prognozė

Vidutinis 28.77 USD  4.96%

Aukščiausias 35.46 USD

Žemiausias 25 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pfizer kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

21 ratings

7

Pirkti

12

Laikyti

2

Parduoti

Techninis įvertinimas

By Trading Central

22.855 / 23.85Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

275 / 350 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat